HighTower Advisors
HEPA

HighTower Advisors’s Hepion Pharmaceuticals HEPA Stock Holding History

HighTower Advisors’s Portfolio HEPA Stock Details HEPA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-1
Closed -$23K – 2441
2019
Q1 		$23K Sell
1
-1
-50% -$19.4K ﹤0.01% 2174
2018
Q4 		$37K Hold
2
– – ﹤0.01% 2049
2018
Q3 		$73K Hold
2
– – ﹤0.01% 2092
2018
Q2 		$169K Hold
2
– – ﹤0.01% 1935
2018
Q1 		$244K Hold
2
– – ﹤0.01% 1773
2017
Q4 		$374K Hold
2
– – ﹤0.01% 1586
2017
Q3 		$540K Hold
2
– – ﹤0.01% 1395
2017
Q2 		$608K Hold
2
– – 0.01% 1283
2017
Q1 		$1.85M Hold
2
– – 0.02% 783
2016
Q4 		$1.26M Buy
+2
New +$2.02M 0.01% 881
2015
Q4 		– Hold
0
– -$27K – 2085
2015
Q3 		– Hold
0
– – – 1801

Other funds holding HEPA

VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HighTower Advisors's HEPA Position: Q2 2019 in Review

HighTower Advisors sold out of Hepion Pharmaceuticals (HEPA) in Q2 2019, closing a stake of 1 share — an estimated $23K sold.

HighTower Advisors first reported a position in HEPA in Q4 2016 and held it in 10 quarters. The position peaked at $1.85M in Q1 2017. 4 funds tracked by Wall St. Rank hold HEPA as of Q2 2019.

  • HighTower Advisors reported no remaining Hepion Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • HighTower Advisors sold 1 Hepion Pharmaceuticals share in Q2 2019, an estimated $23K.
  • HighTower Advisors first reported a position in Hepion Pharmaceuticals in Q4 2016 and held it in 10 quarters.
  • HighTower Advisors's Hepion Pharmaceuticals position peaked at $1.85M in Q1 2017.
  • 4 funds tracked by Wall St. Rank held Hepion Pharmaceuticals as of Q2 2019.

Based on HighTower Advisors's 13F filing for Q2 2019, filed 13 Aug 2019.